Today: 7 February 2026
Subscribe
Browse Category

Biotechnology News 7 December 2025 - 9 December 2025

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and 760-Dollar Target: December 9, 2025 Stock Deep Dive

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and 760-Dollar Target: December 9, 2025 Stock Deep Dive

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) has turned into one of 2025’s most dramatic biotech stories. On December 9, 2025, the stock is trading around $265–270 per share, near its 52‑week high of about $278 and far above its low near $26.70, giving the company a market capitalization of roughly $6.6 billion.StockAnalysis+1 Behind that move is a mix of powerful late‑stage clinical data, accelerating FDA interactions, increasingly aggressive analyst targets — including a new $760 price target from Guggenheim — and a growing cloud of controversy after a short‑seller attack on Praxis’s lead program.Quiver Quantitative+2Investing.com+2 Here is a detailed, news-style
9 December 2025
·····
Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Updated: December 9, 2025 Kymera Therapeutics’ stock has just done the biotech equivalent of a backflip: a ~40–50% one‑day surge on Monday after stunning eczema trial data, followed almost immediately by a cool‑down triggered by a $500 million stock offering and a wave of fresh analyst price‑target hikes.GlobeNewswire+3Investing.com+3Investing.com+3 This is the kind of setup that gets both momentum traders and long‑term biotech nerds leaning in. Where KYMR Stock Stands Today The immediate driver: KT‑621, Kymera’s oral STAT6 degrader, produced dupilumab‑like efficacy in atopic dermatitis (eczema) with clean safety in a small Phase 1b trial — and the Street went into
9 December 2025
·····
Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook

Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook

Structure Therapeutics Inc. (NASDAQ: GPCR) has suddenly become one of the most talked‑about obesity‑drug names on Wall Street. As of mid‑day on December 9, 2025, Structure Therapeutics stock was trading around $69.98, up roughly 100% in a single session after the company unveiled strong mid‑stage data for its once‑daily oral GLP‑1 obesity pill, aleniglipron. GlobeNewswire+2Investors+2 Over the past six months, GPCR has already delivered a multi‑bagger move, with one analyst note calculating a ~241% gain even before today’s opening bell. The stock now sits near its 52‑week high, with a 52‑week range of about $13.22 to $94.90 and a market
9 December 2025
····
iBio (IBIO) Stock Jumps on Obesity Drug Momentum: All the Latest News, Analyst Targets and 2026–2027 Outlook (December 9, 2025)

iBio (IBIO) Stock Jumps on Obesity Drug Momentum: All the Latest News, Analyst Targets and 2026–2027 Outlook (December 9, 2025)

As of December 9, 2025, iBio, Inc. (NASDAQ: IBIO) has turned into one of the louder tickers in the obesity‑drug corner of biotech. After closing Monday, December 8 at $1.67, up 39% on the day, IBIO is trading higher again in pre‑market action on Tuesday, with quotes between $1.76 and $1.81, pushing its market value to roughly $37–38 million.Benzinga The rally caps a run of pipeline, funding and analyst updates that have dramatically changed how the market is looking at this tiny, pre‑revenue biotech. Key takeaways for IBIO stock today This is still a high‑risk, preclinical nano‑cap, but it now
9 December 2025
····
Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough and $250M Equity Offering

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough and $250M Equity Offering

Wave Life Sciences Ltd. (NASDAQ: WVE) has suddenly gone from sleepy small‑cap biotech to front‑page obesity contender. After unveiling striking Phase 1 data for its RNA obesity drug WVE‑007 on December 8, 2025, the stock rocketed roughly 147% to about $18.52 per share, pushing the company’s market cap to around $3.0 billion as of early December 9. MLQ At the same time, Wave launched a $250 million public equity offering, setting up a dramatically stronger balance sheet—but also introducing dilution right after the rally. GlobeNewswire Below is a detailed look at what just happened, why WVE stock is suddenly in
9 December 2025
····
Pfizer (PFE) Stock Today: Hemophilia Breakthrough, Metsera Deal and AI Cost Cuts – Price, Forecast and News for December 8, 2025

Pfizer (PFE) Stock Today: Hemophilia Breakthrough, Metsera Deal and AI Cost Cuts – Price, Forecast and News for December 8, 2025

Pfizer Inc. (NYSE: PFE) is back in focus on December 8, 2025, as investors digest fresh clinical data in hemophilia, big strategic bets in obesity drugs, and an aggressive, AI‑driven cost‑cutting program – all while the stock continues to trade at a high dividend yield and a discount to many Big Pharma peers. As of Monday morning, Pfizer shares are trading around $26 per share, slightly lower on the day and roughly in the middle of their 52‑week range of $20.92–$27.69. That range implies a market capitalization of about $148 billion, a price‑to‑earnings (P/E) ratio near 15x, and relatively low
8 December 2025
···
Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough – What the New Data and Wall Street Forecasts Signal

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough – What the New Data and Wall Street Forecasts Signal

Published: December 8, 2025 WVE stock more than doubles on massive volume Wave Life Sciences Ltd. (NASDAQ: WVE) staged a spectacular rally on Monday after unveiling positive interim data from its Phase 1 INLIGHT trial for obesity drug candidate WVE‑007. Shares surged from a close of $7.49 on Friday, December 5 to intraday levels around $17–18, a gain in the range of 120%–140% and a new multi‑year high. Yahoo Finance+2Investing.com+2 Trading volume blew out to more than 100 million shares, roughly 40 times the stock’s recent average daily volume of about 2.5 million, underscoring intense speculative interest and likely short
8 December 2025
···
Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics Inc. (NASDAQ: GPCR) just turned a long‑anticipated clinical readout into a full‑blown stock market event. On Monday, December 8, 2025, the company released positive topline data from its ACCESS program for aleniglipron (GSBR‑1290), a once‑daily oral GLP‑1 receptor agonist for obesity. The market response was immediate: GPCR closed at $69.46, up about 101% on the day, after trading between $24.83 and an intraday high of $94.90. That move vaulted Structure into the front rank of the oral obesity drug race and forced investors, analysts and competitors to update their models in real time. Who is Structure Therapeutics and
8 December 2025
·····
Recursion Pharmaceuticals (RXRX) Stock Jumps on Positive FAP Trial Data: Latest News, AI Drug Discovery Outlook and Analyst Forecasts

Recursion Pharmaceuticals (RXRX) Stock Jumps on Positive FAP Trial Data: Latest News, AI Drug Discovery Outlook and Analyst Forecasts

Recursion Pharmaceuticals’ stock is back in the spotlight on 8 December 2025 after the company reported encouraging mid‑stage trial results for its AI‑discovered drug REC‑4881 in a rare, cancer‑linked condition called familial adenomatous polyposis (FAP). The news gives investors something they’ve been waiting on for years: early clinical proof that Recursion’s AI‑driven platform might actually work in real patients. GlobeNewswire+1 Shares of Recursion (ticker: RXRX) traded in the mid‑$4 range on Monday, up low single digits intraday after jumping as much as around 6% in pre‑market trading on the back of the data, according to Reuters and Benzinga. Reuters+1 Below
8 December 2025
·····
SELLAS Life Sciences (SLS) Stock on December 8, 2025: ASH 2025 Data, Cash Runway and Analyst Targets Over $6

SELLAS Life Sciences (SLS) Stock on December 8, 2025: ASH 2025 Data, Cash Runway and Analyst Targets Over $6

Market data in this article are as of December 8, 2025, 09:13 UTC. Where SLS Stock Stands Today SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is trading at around $1.74 per share in early trading on December 8, 2025, barely changed from the previous close. The company’s profile today looks roughly like this: That backdrop sets the stage for today’s key driver: new Phase 2 data for SLS009, presented at the American Society of Hematology (ASH) 2025 meeting and widely covered in financial media over December 7–8. Fresh Catalyst on December 8, 2025: SLS009 Delivers 46% Response Rate in Tough
8 December 2025
····
Gilead Sciences (GILD) Stock: 7 Things to Know Before the Market Opens on December 8, 2025

Gilead Sciences (GILD) Stock: 7 Things to Know Before the Market Opens on December 8, 2025

Gilead Sciences (NASDAQ: GILD) heads into Monday’s session riding an event‑packed weekend: new cancer data at the ASH 2025 hematology meeting, fresh institutional‑ownership filings, and another round of valuation work from analysts and quant platforms. Here’s what investors should know about Gilead Sciences stock before the U.S. market opens on Monday, December 8, 2025. 1. Price action: defensive biotech near the top of its range As of the close on Friday, December 5, Gilead Sciences stock finished at $121.22, about 1.14% lower on the day; after‑hours trading nudged it slightly higher to ~$121.34. TechStock² At that level: Several recent analyses
8 December 2025
····
Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Updated: December 7, 2025 – For informational purposes only, not investment advice. 1. VRTX stock snapshot as of early December 2025 Vertex Pharmaceuticals (NASDAQ: VRTX) has had a busy—and volatile—2025. As of the close on Friday, December 5, 2025, VRTX shares finished around $455.48, giving the company a market value in the $115–117 billion range.Stock Titan+3MacroTrends+3StockInvest+3 Key numbers investors are watching right now: Technically, several short‑term models still classify VRTX as a “buy or hold candidate”: StockInvest.us, for example, highlights a strong short‑term uptrend, with the price up almost 8% over the past two weeks and an estimated 3‑month target
7 December 2025
···
1 … 12 13 14 15 16 … 25

Stock Market Today

Ashtead share price in focus as buyback rolls on and NYSE switch clocks closer

Ashtead share price in focus as buyback rolls on and NYSE switch clocks closer

7 February 2026
Ashtead shares closed Friday at 4,936p, up 1.09%, after the company bought 88,872 shares under its repurchase program. The group is set to shift its primary listing to New York on March 2, pending court approval, and will be removed from the FTSE UK index the same day. Ashtead paid a half-year dividend of 37.5 U.S. cents per share on Friday.
Beazley share price: big funds reshuffle stakes as Zurich bid deadline nears

Beazley share price: big funds reshuffle stakes as Zurich bid deadline nears

7 February 2026
Beazley shares closed flat at 1,236 pence Friday as BlackRock disclosed a 6.55% stake and Vanguard reported 5.02%. Wellington Management cut its holding below 5%. The disclosures follow Zurich Insurance’s possible takeover offer of up to 1,335 pence per share, with a Feb. 16 deadline for a firm bid.
Go toTop